Critical considerations for allogeneic cell therapy scale up

Cell Gene Therapy Insights 2018; 4(11), 1081-1086.

10.18609/cgti.2018.113

Published: 18 December 2018
Editorial
Sharon Grimster

Sharon Grimster joined ReNeuron in 2013 and was subsequently appointed as General Manager of the Wales facility in September 2014. Sharon has significant experience in pharmaceutical development, and she has particular expertise in ATMPs, project management, biologics development and manufacturing. Prior to working at ReNeuron, Sharon held senior team roles at Celltech, Antisoma and F-star, and has had responsibility for a range of development functions, including project management, regulatory affairs, manufacturing, quality and general operations. Sharon qualified as a coach at the Henley Business School and has a BSc from the University of Leicester and a Diplomas in Immunology and in Management Studies. She is also a Fellow of the Royal Society of Biology and an active member of a number of significant industry committees.